Trials / Completed
CompletedNCT02453516
The Effect of the Serratus Block on Pain Control After Breast Surgery
The Effect of The Serratus Block on Analgesia After Breast Surgery A Randomized Controlled Double-Blinded Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Women's College Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Surgery for breast cancer is associated with significant pain. The serratus nerve block targets the interfascial plane either below or above the serratus muscle, blocking thereby the lateral cutaneous branches of the intercostal nerves. The purpose of this randomized controlled double-blinded study is to see whether the addition of a serratus nerve block to a general anesthesia results in a better postoperative pain control in patients undergoing surgery for breast cancer.
Detailed description
The prevalence of severe acute postoperative pain after breast surgery is high. Regional anesthesia has the potential to provide superior pain relief with fewer side effects compared to standard systemic opioid therapy. The search for a regional anesthesia technique for breast surgery has been ongoing as this technique needs to be time efficient, relatively risk-free and also practicable in an out-patient setting. The serratus block is a promising technique that may combine these advantages.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Serratus Block | Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles |
| PROCEDURE | Placebo Block | Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line |
| DRUG | ropivacaine | Drug indicated for regional anesthesia |
| DRUG | epinephrine | Drug indicated to prolong the action of regional anesthesia |
| OTHER | sterile saline | Neutral injection (no drug involved) |
Timeline
- Start date
- 2014-10-29
- Primary completion
- 2019-09-11
- Completion
- 2019-12-11
- First posted
- 2015-05-25
- Last updated
- 2020-01-13
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02453516. Inclusion in this directory is not an endorsement.